Can Paxil (Paroxetine) or Losartan Potassium Cause Erectile Dysfunction?
Yes, Paxil (paroxetine) clearly causes erectile dysfunction, while losartan potassium does not cause erectile dysfunction and may actually improve it.
Paroxetine (Paxil) and Erectile Dysfunction
Paroxetine definitively causes erectile dysfunction as a well-documented adverse effect of SSRI therapy. 1
Incidence Rates from FDA Data
- Impotence occurs in 2-9% of males taking paroxetine compared to 0-3% on placebo 1
- Ejaculatory disturbance affects 13-28% of males versus 0-2% on placebo 1
- Decreased libido occurs in 6-15% of males compared to 0-5% on placebo 1
- In females, decreased libido occurs in 0-9% versus 0-2% on placebo, and orgasmic disturbance in 2-9% versus 0-1% 1
Dose-Response Relationship
- Fixed-dose studies show that impotence and abnormal ejaculation increase with higher doses (20 mg vs 40 mg) in posttraumatic stress disorder patients 1
- Abnormal ejaculation also increases with dose in generalized anxiety disorder patients 1
Clinical Guideline Recognition
- SSRIs including paroxetine are recognized as drugs associated with erectile dysfunction in hypertension management guidelines 2
- The NCCN guidelines acknowledge that SSRIs (including paroxetine) are used to treat premature ejaculation, not erectile dysfunction, and can cause sexual dysfunction as a side effect 2
Important Caveat
The FDA label explicitly states that "estimates of the incidence of untoward sexual experience and performance cited in product labeling are likely to underestimate their actual incidence" because patients and physicians may be reluctant to discuss these issues 1
Losartan Potassium and Erectile Dysfunction
Losartan does not cause erectile dysfunction and evidence suggests it may actually improve erectile function.
Evidence Against Causation
- The JNC 7 guidelines note that diuretics were associated with sexual dysfunction in some studies, but ACE inhibitors and ARBs (including losartan) have not been observed to increase the incidence of erectile dysfunction 2
- The 2017 ACC/AHA guidelines recognize that some antihypertensive medications affect erectile dysfunction more than others, but with modern treatment options, drug class distinctions are less relevant 2
Evidence for Improvement
- A prospective study of 82 hypertensive men with erectile dysfunction showed that losartan improved sexual satisfaction from 7.3% to 58.5% after 12 weeks of treatment 3
- Subjects reporting high frequency of sexual activity improved from 40.5% to 62.3% with losartan treatment 3
- 73.7% of subjects reported improvement in quality of life with losartan therapy 3
- A clinical trial in diabetic patients demonstrated that losartan significantly improved IIEF-5 scores, with patients having moderate and mild ED showing better response rates 4
- Evidence suggests that losartan and doxazosin have a positive effect on erectile function and may decrease the incidence of ED in hypertensive patients 5
Mechanism
The beneficial effect is likely related to losartan's action as an angiotensin II receptor blocker, as activation of the cavernous local renin-angiotensin system plays a role in diabetic erectile dysfunction 4
Clinical Management Implications
For Patients on Paroxetine with ED
- Add a PDE5 inhibitor (sildenafil, tadalafil, vardenafil, or avanafil) as first-line treatment unless contraindicated, allowing continuation of necessary psychiatric medication 6
- Screen for nitrate use and assess cardiovascular risk before prescribing PDE5 inhibitors 6
- Combination therapy of paroxetine with tadalafil has been shown effective for patients with both premature ejaculation and erectile dysfunction 7
For Hypertensive Patients with ED
- Consider losartan as a preferred antihypertensive agent in patients with erectile dysfunction, as it does not worsen and may improve erectile function 3, 5
- If ED develops on other antihypertensive medications (particularly beta-blockers or diuretics), switching to losartan may be beneficial 2, 5
- Combination therapy of losartan plus tadalafil appears more effective than monotherapy for diabetic patients with ED 4